Skip to main content
Journal cover image

Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.

Publication ,  Journal Article
Gedeon, PC; Champion, CD; Rhodin, KE; Woroniecka, K; Kemeny, HR; Bramall, AN; Bernstock, JD; Choi, BD; Sampson, JH
Published in: Expert Rev Clin Pharmacol
October 2020

INTRODUCTION: Despite maximal surgical resection and chemoradiation, glioblastoma (GBM) continues to be associated with significant morbidity and mortality. Novel therapeutic strategies are urgently needed. Given success in treating multiple other forms of cancer, checkpoint inhibitor immunotherapy remains foremost amongst novel therapeutic strategies that are currently under investigation. AREAS COVERED: Through a systematic review of both published literature and the latest preliminary data available from ongoing clinical studies, we provide an up-to-date discussion on the immune system in the CNS, a detailed mechanistic evaluation of checkpoint biology in the CNS along with evidence for disruption of these pathways in GBM, and a summary of available preclinical and clinical data for checkpoint blockade in GBM. We also include a discussion of novel, emerging targets for checkpoint blockade which may play an important role in GBM immunotherapy. EXPERT OPINION: Evidence indicates that while clinical success of checkpoint blockade for the treatment of GBM has been limited to date, through improved preclinical models, optimization in the context of standard of care therapies, assay standardization and harmonization, and combinatorial approaches which may include novel targets for checkpoint blockade, checkpoint inhibitor immunotherapy may yield a safe and effective therapeutic option for the treatment of GBM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Clin Pharmacol

DOI

EISSN

1751-2441

Publication Date

October 2020

Volume

13

Issue

10

Start / End Page

1147 / 1158

Location

England

Related Subject Headings

  • Pharmacology & Pharmacy
  • Molecular Targeted Therapy
  • Immunotherapy
  • Immune Checkpoint Inhibitors
  • Humans
  • Glioblastoma
  • Brain Neoplasms
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gedeon, P. C., Champion, C. D., Rhodin, K. E., Woroniecka, K., Kemeny, H. R., Bramall, A. N., … Sampson, J. H. (2020). Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol, 13(10), 1147–1158. https://doi.org/10.1080/17512433.2020.1817737
Gedeon, Patrick C., Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, and John H. Sampson. “Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.Expert Rev Clin Pharmacol 13, no. 10 (October 2020): 1147–58. https://doi.org/10.1080/17512433.2020.1817737.
Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, et al. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol. 2020 Oct;13(10):1147–58.
Gedeon, Patrick C., et al. “Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.Expert Rev Clin Pharmacol, vol. 13, no. 10, Oct. 2020, pp. 1147–58. Pubmed, doi:10.1080/17512433.2020.1817737.
Gedeon PC, Champion CD, Rhodin KE, Woroniecka K, Kemeny HR, Bramall AN, Bernstock JD, Choi BD, Sampson JH. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Rev Clin Pharmacol. 2020 Oct;13(10):1147–1158.
Journal cover image

Published In

Expert Rev Clin Pharmacol

DOI

EISSN

1751-2441

Publication Date

October 2020

Volume

13

Issue

10

Start / End Page

1147 / 1158

Location

England

Related Subject Headings

  • Pharmacology & Pharmacy
  • Molecular Targeted Therapy
  • Immunotherapy
  • Immune Checkpoint Inhibitors
  • Humans
  • Glioblastoma
  • Brain Neoplasms
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences